A Combination of Exercise and Therapy
with Cabergoline Attenuate Disturbances
of Pituitary-Gonadal Hormones in
Hyperprolactinemic Male Patients

Mohammad Fayiz AbuMoh'd; Samir Qasim; Nesreen Bataineh; Loay Salman

Mohammad Fayiz AbuMoh'd¹, Samir Qasim¹, Nesreen Bataineh², Loay Salman³

¹Yarmouk University, Faculty of Physical Education, Department of Sports/Movement Sciences, Irbid, Jordan
²Yarmouk University, Faculty of Medicine, Department of Basic Medical Sciences, Irbid, Jordan
³Jordan University of Science and Technology, Faculty of Medicine, Department of Basic Medical Sciences, Irbid, Jordan

A Combination of Exercise and Therapy with Cabergoline Attenuate Disturbances of Pituitary-Gonadal Hormones in Hyperprolactinemic Male Patients

Monten. J. Sports Sci. Med. 2020, 9(2), 35-41 | DOI: 10.26773/mjssm.200906

Abstract

This study aimed to investigate whether cabergoline therapy alone for six months or in combination with a light exercise programme for an additional three months can attenuate hyperprolactinemia in 13 male patients (range: 22 to 45 yrs.) through measuring pituitary-gonadal hormones including prolactin, follicle-stimulating hormone, luteinizing hormone, and total testosterone. The exercise programme consisted of walking, brisk walking, jogging, and running for three months, during which the intensity and duration of exercise were gradually increased. All the patients performed the exercise programme at 6.30 AM to exclude the effects of the circadian rhythm. The exercise programme was performed at an intensity below 160 beats per min to ensure filling of the heart with blood during ventricular diastole. Blood samples were collected from each patient on three occasions: before treatment, at the end of cabergoline therapy, and after the combination of light exercise and cabergoline. At the end of cabergoline therapy, descriptive data revealed that serum prolactin levels were decreased while the other hormones were increased but without returning to the normal range, except for one patient. However, at the end of the combination procedure, most hormones, namely prolactin and testosterone, were returned to the normal range in most patients. In conclusion, light exercise combined with cabergoline therapy for additional 3 months after 6 months of cabergoline therapy alone returned hormones in most patients to normal range probably due to improved mood and decreased hostility as a result of tuberoinfundibular pathway activity.

Keywords

hypogonadism, hypoglycaemia, tuberoinfundibular pathway, acetylcholine, galactorrhoea

View full article
(PDF – 156KB)

References

Abbiss, C. R., & Laursen, P. B. (2005). Models to explain fatigue during prolonged endurance cycling. Sports Medicine, 35(10), 865-898. https://doi.org/10.2165/00007256-200535100-00004

Alpak, G., Unal, A., Bulbul, F., Akosy, I., Demir, B., & Svas, H. A. (2014). Hyperprolactinemia due to paliperdone palmitate and treatment with Aripiprazole. Bulletin of Clinical Psychopharmacology, 24(3), 253-256. https://doi.org/10.5455/bcp.20131213042842

Bailey, S. P., Davis, J. M., & Ahlborn, E. N. (1993). Neuroendocrine and substrate responses to altered brain 5-HT activity during prolonged exercise to fatigue. Journal of Applied Physiology, 74(6), 3006-3012. https://doi.org/10.1152/jappl.1993.74.6.3006

Barker, J. B., Mellaliey, S. D., McCarthy, P. J., Jones, M. V., & Moran, A. (2013). A review of single-case research in sport psychology 1997-2012: Research trends and future directions. Journal of Applied Sport Psychology, 25(1), 4-32. https://doi.org/10.1080/10413200.2012.709579

Buckworth, J., Dishman, R. K., O'Connor, P. J., & Tomporowski, P. D. (2013). Exercise psychology. 2nd edition. Champaign, IL: Human Kinetics.

Chapurin, N., Wang, C., Steinberg, D. M., & Jang, D. W. (2016). Hyperprolactinemia secondary to allergic fungal sinusitis compressing the pituitary gland. Case Reports in Otolaryngology, 2016, 1-3. https://doi.org/10.1155/2016/7260707

Dogan, A. B., Arduc, A., Tuna, M. M., Nasiroglu, I. N., Isik, S., Berker, D., & Guler, S. (2016). Evaluation of atherosclerosis after cessation of cabergoline therapy in patients with prolactinoma. Anatolian Journal of Cardiology, 16, 440-447. https://doi.org/10.5152/AnatolJCardiol.2015.6416

EL-Beheiry, A., Souka, A., EL-Kamshoushi, A., Hussein, S., & EL-Sabah, K. (1988). Hyperprolactinemia and impotence. Archives of Andrology, 21, 211-214. https://doi.org/10.3109/01485018808986743

Ghadirian, H., Shirani, M., Ghazi-Mirsaeed, S., Mohebi, S., & Alimohamadi, M. (2018). Pituitary apoplexy during treatment of prolactinoma with cabergoline. Asian Journal Neurosurgery, 13(1), 93-95. https://doi.org/10.4103/1793-5482.181130

Grossman, A., & Sutton, J. R. (1985). Endorphins: What are they? How are they measured? What is their role in exercise? Medicine & Science in Sports & Exercise, 17, 74-81.

Gulleroglu, K., Olgac, A., Bayrakci, U., Erdogan, O., Kinik, S. T., & Baskin, E. (2012). Hyperprolactinemia as a rare cause of hypertension in chronic renal failure. Renal Failure, 34(6), 792-794. https://doi.org/10.3109/0886022X.2012.672313

Inci Kenar, A. N., & Sozeri Varma, G. (2014). Hyperprolactinemia with Aripiprazole: a case report and review of the literature. Bulletin of Clinical Psychopharmacology, 24(3), 257-260. https://doi.org/10.5455/bcp.20131021025639

Ishikawa, H., Kaneko, S., Ohashi, M., Nakagawa, K., & Hata, M. (1993). Retrograde ejaculation accompanying hyperprolactinemia. Archives of Andrology, 30, 153-155. https://doi.org/10.3109/01485019308987749

Khare, S., Lila, A. R., Patil, R., Phadke, M., Kerkar, P., Bandgar, T., & Shah, N. S. (2017). Long-term cardiac (valvulopathy) safety of cebergoline in prolactinoma. Indian Journal of Endocrinology and Metabolism, 21(1), 154-159. https://doi.org/10.4103/2230-8210.196010

Kilic, A., Ozturk, A., Deveci, E., & Nrpinar, I. (2018). Development of hyperprolactinemia induced by the addition of Bupropion to Venlafaxine XR treatment. Bezmialem Science, 6, 150-152. https://doi.org/10.14235/bs.2018.1119

Kulshreshtha, B., Pahuja, I., Kothari, D., Sharma, N., Gupta, S., & Mittal, A. (2017). Menstrual cycle abnormalities in patients with prolactinoma and drug-induced hyperprolactinemia. Indian Journal of Endocrinology and Metabolism, 21(4), 545-550. https://doi.org/10.4103/ijem.IJEM_515_16

Laufer, N., Margalioth, E. J, Livshin, J., Ben-David, M., & Schenker, J. G. (1981). Effect of bromocriptine treatment on male infertility associated with hyperprolactinemia. Archives of Andrology, 6, 343-346. https://doi.org/10.3109/01485018108987547

Majumdar, A., & Mangal, N. S. (2013). Hyperprolactinemia. Journal of Human Reproductive Sciences, 6(3), 168-175. https://doi.org/10.1007/978-81-322-1686-5_29

Nishimura, K., Matsumiya, K., Tsuboniwa, M., Koga, M., Miura, H., Tsujimura, A., Uchida, K., Kondoh, N., Kitamura, M., & Okuyama, A. (1999). Bromocriptine for infertile males with mild hyperprolactinemia: hormonal and spermatogenic effects. Archives of Andrology, 43, 207-213. https://doi.org/10.1080/014850199262517

Oldham, J. S., Zimmerman, J. B., & Hotfield, B. D. (2019). Depression and anxiety disorders. In: Moore, G. E, Durstine, J. L., & Painter, P. L. (eds). Exercise management for persons with chronic disease and disabilities USA, American college of sports medicine: Human Kinetics (293-300). https://doi.org/10.1249/01.mss.0000320868.98282.42

Page, J., & Thelwell, R. (2013). The value of social validation in single case methods in sport and exercise psychology. Journal of Applied Sport Psychology, 25(1), 61-71. https://doi.org/10.1080/10413200.2012.663859

Palubska, S., Adamiak-Godlewska, A., Winkler, I., Romanek-Piva, K., Rechberger, T., & Gogacz, M. (2017). Hyperprolactinemia - a problem in patients from the reproductive period to the menopause. Menopause Reviw, 16(1), 1-7. https://doi.org/10.5114/pm.2017.67364

Panidis, D., Rousso, D., Skiadopoulos, S., Panidou, E., & Mamopoulos, M. (1997). Evaluation of semen parameters in men with hyperprolactinemia induced by Metoclopramide. Archives of Andrology, 39, 237-242. https://doi.org/10.3109/01485019708987922

Raveendranthan, D., Rao, N. P., Rao, M. G., Mangot, A. G., Varambally, S., Kesavan, M., Venkatasubramanian, G., & Gangadhar, B. N. (2018). Add-on Aripiprazole for atypical antipsychotic-induced-clinically significant hyperprolactinemia. Indian Journal of Psychological Medicine, 40(1), 38-40. https://doi.org/10.4103/IJPSYM.IJPSYM_147_17

Sharma, N., Dutta, D., & Sharma, L. K. (2017). Hyperpolactinemia in children with subclinical hypothyroidism. Journal of Clinical Research in Pediatric Endocrinology, 9(4), 350-354. https://doi.org/10.4274/jcrpe.4536

Sperling, S., & Bhatt, H. (2016). Prolactinoma: a massive effect on bone mineral density in a young patient. Case Reports in Endocrinology, 2016, 1-3. https://doi.org/10.1155/2016/6312621

Tirgar-Tabari, S., Sharbatdaran, M., Manafi-Afkham, S., & Montazeri, M. (2016). Hyperprolactinemia and hirsutism in patients without polycyctic ovary syndrome. International Journal of Trichology, 8(3), 130-134. https://doi.org/10.4103/0974-7753.188998

Toulis, K. A., Robbins, T., Reddy, N., Balachandra, K., Gokhale, H., Cheng, K. K., Karavitaki, N., Wass, J., & Nirantharakumar, K. (2018). Males with prolactinoma are at increased risk of incident cardiovascular disease. Clinical Endocrinology, 88, 71-76. https://doi.org/10.1111/cen.13498

Yamashita, M., & Yamamoto, T. (2014). Tryptophan and kynurenic acid may produce an amplified effect in central fatigue induced by chronic sleep disorder. International Journal of Tryptophan Research, 7, 9-14. https://doi.org/10.4137/IJTR.SI4084

Yancar-Demir, E., & Sayin, A. (2014). Prolongation of hyperprolactinemia by Clozapine: a case report. Bulletin of Clinical Psychopharmacology, 24(4), 371-375. https://doi.org/10.5455/bcp.20131127065702